Oracle is forecasting a significant acceleration in growth through 2030, owing to the terrific demand for its cloud infrastructure. Importantly, Oracle seems to have a big-enough contract backlog that ...

[BRIEFING.COM] S&P futures vs fair value: -4.00. Nasdaq futures vs fair value: -56.00. The stock market is now poised for a mixed open, with the S&P 500 futures now trading just four points below fair ...

Meta (NASDAQ: META) will discuss its artificial intelligence ambitions, user growth figures, and more during a critical investor update. *Stock prices used were the afternoon prices of Oct. 23, 2025.

If you use Excel 40 hours a week (and those are the weeks you are on vacation), welcome to the MrExcel channel. Home to 2,400 free Excel tutorials. Bill "MrExcel" Jelen is the author of 67 books about ...

Nvidia is the dominant force in the data center GPU market. Soaring data center spending is expected to rise to between $3 trillion and $4 trillion by the end of the decade. The stock is still ...

[BRIEFING.COM] The S&P 500 (-0.1%), Nasdaq Composite (+0.3%), and DJIA (-0.1%) are rebounding from session lows that followed commentary from Fed Chair Powell on the future path of monetary policy. In ...

Analysts provided their opinion on this tech giant, following the Q3 earnings report. “In the third quarter, IBM delivered strong results across revenue, profit, and free cash flow, exceeding our ...

The silver price surged during Q3, climbing to near-record highs before surpassing them at the start of Q4. The white metal was influenced by many of the same factors as gold, including interest rate ...

ASML is rated Hold, reflecting strong fundamentals, cash generation, and unique market dominance in advanced lithography for AI-driven chip demand. ASML benefits from robust pricing power and ...

It’s a bad sign that retail investors so eagerly bought last week’s stock-market dip. Mark Hulbert is a columnist for MarketWatch. His Hulbert Ratings service tracks investment newsletters that pay a ...

Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...